WHO prequalifies Celltrion’s trastuzumab biosimilar Herzuma

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

WHO prequalifies Celltrion’s trastuzumab biosimilar Herzuma

Biosimilares/General | Posted 04/09/2020 0 Post your comment

The World Health Organization (WHO) has prequalified Celltrion Healthcare’s second biosimilar, a trastuzumab biosimilar sold as Herzuma.

WHO’s prequalification of medicines is a service provided by the organization to assess the quality, safety and efficacy of medicinal products. It was started in 2002 in partnership with UNAIDS (Joint United Nations Programme on HIV/AIDS), UNICEF (United Nations Children's Fund) and the UN Population Fund, with support from the World Bank [1].

The first biosimilar to be prequalified by WHO was a trastuzumab biosimilar produced by Samsung Bioepis [2]. Trastuzumab is a monoclonal antibody treatment for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric cancer. On 11 June 2020, WHO prequalified a further trastuzumab biosimilar produced by Mylan Pharmaceuticals.

On 14 July 2020, WHO announced the prequalification of a third trastuzumab biosimilar – Herzuma, which is produced by the South Korean biotechnology company Celltrion Healthcare. Herzuma was launched in the US in March 2020 [3] and has been prequalified by WHO in two doses, 150 mg and 420 mg.

This is the second of Celltrion’s biosimilars to be prequalified by WHO. In May 2020, WHO prequalified Celltrion’s rituximab biosimilar, Truxima [4].

Rituximab is an antibody treatment for autoimmune diseases including rheumatoid arthritis and cancers of the blood. Celltrion’s rituximab was the first biosimilar version to be prequalified by WHO, see Table 1.

Table 1: WHO prequalified biosimilars as of 21 August 2020
Product	Dosage/strength	Licensed to	Date of prequalification
Rituximab	Concentrate for solution for infusion*	Celltrion	25 May 2020
Trastuzumab	Powder for concentrate for solution for infusion, 150 mg and 420 mg	Celltrion	14 July 2020
Trastuzumab	Powder for concentrate for solution for infusion, 150 mg	Mylan	11 June 2020
Trastuzumab	Powder for concentrate for solution for infusion, 150 mg	Samsung Bioepis	18 December 2019
*The World Health Organization (WHO) does not give a strength for this in their list of PQ products.

Related articles
Celltrion launches Truxima in Brazil

Celltrion to build facility in China and increase new drug output

WHO prequalification for rituximab and trastuzumab: first results

References
1. GaBI Online - Generics and Biosimilars Initiative. WHO launches consultation on prequalification of biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Sep 4]. Available from: www.gabionline.net/Biosimilars/General/WHO-launches-consultation-on-prequalification-of-biosimilars
2. GaBI Online - Generics and Biosimilars Initiative. WHO prequalifies first biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Sep 4]. Available from: www.gabionline.net/Biosimilars/General/WHO-prequalifies-first-biosimilar
3. GaBI Online - Generics and Biosimilars Initiative. Celltrion/Teva launch trastuzumab biosimilar Herzuma in US [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Sep 4]. Available from: www.gabionline.net/Biosimilars/News/Celltrion-Teva-launch-trastuzumab-biosimilar-Herzuma-in-US
4. GaBI Online - Generics and Biosimilars Initiative.WHO prequalifies first rituximab biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Sep 4]. Available from: www.gabionline.net/Biosimilars/General/WHO-prequalifies-first-rituximab-biosimilar

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.